2nd Quarter - Report — CEPHEID for CEPHEID (2022)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$140,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

issues related to diagnostic testing, issues related to responding to the current COVID-19 pandemic and future pandemics; S. 2209/H.R. 4128, the Verifying Accurate Leading-Edge IVCT Development Act of 2021 (VALID); S. 3799 the PREVENT Pandemics Act; H.R. 6851, No Surprises for COVID-19 Tests Act.

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—
ANGELA STEWART	Legislative Counsel, Senator John W. Warner (R-VA)

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 4128 (117th), S. 3799 (117th), S. 2209 (117th), H.R. 6851 (117th)

Medicare/Medicaid MMM

issues related to diagnostic testing and reimbursement related to COVID testing

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—
ANGELA STEWART	Legislative Counsel, Senator John W. Warner (R-VA)

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.